This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Alkermes accused in US court maintaining illegal monopoly for anti-opioid treatment

( October 2, 2025, 19:59 GMT | Official Statement) -- MLex Summary: Value Drug Company has filed a US antitrust complaint accusing Alkermes of illegally prolonging its monopoly in the injectable naltrexone market and protecting its brand Vivitrol monopoly profits from AB-rated generic competition. The complaint claims that Alkermes obtained a relevant patent by fraud and took various additional anticompetitive actions thereafter to unlawfully exclude generic competition and preserve its brand Vivitrol monopoly revenues.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections